Xocova (ensitrelvir) is an oral antiviral indicated for the prevention and treatment of COVID-19 due to SARS-CoV-2 infection. Xocova selectively inhibits the 3CL protease, blocking this essential viral enzyme required for replication, helping to reduce viral load and limit disease progression.
This therapy is a significant advance in the treatment of COVID-19 with an easy-to-take oral medication for early treatment and post-exposure prophylaxis. Xocova is designed to inhibit viral replication at its source, supporting ongoing efforts to reduce the impact of COVID-19 and improve patient outcomes through effective antiviral therapy.
